

PHARMACEUTICALS FOR TARGETING CORONAVIRUSES

Editors:

Luciana Scotti

Marcus T. Scotti

Bentham Books

Pharmaceuticals for Targeting Coronaviruses

Edited by

Luciana Scotti

&

Marcus T. Scotti

*Laboratory of Cheminformatics
Program of Natural and Synthetic Bioactive Products
(PgPNSB)
Health Sciences Center, Federal University of Paraíba
João Pessoa-PB, Brazil*

Pharmaceuticals for Targeting Coronaviruses

Editors: Luciana Scotti & Marcus T. Scotti

ISBN (Online): 978-981-5051-30-8

ISBN (Print): 978-981-5051-31-5

ISBN (Paperback): 978-981-5051-32-2

© 2022, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

PREFACE	i
REFERENCES	ii
LIST OF CONTRIBUTORS	iii
CHAPTER 1 STRUCTURE-BASED DRUG DISCOVERY APPROACHES APPLIED TO SARS-COV-2 (COVID-19)	1
<i>Igor José dos Santos Nascimento, Thiago Mendonça de Aquino and Edeildo Ferreira da, Silva-Júnior</i>	
1. INTRODUCTION	2
2. CORONAVIRUSES: HISTORY AND STRUCTURE	3
3. DRUG DISCOVERY PROCESS	4
4. SBDD STRATEGIES AND DISCOVERY OF HITS AGAINST CORONAVIRUSES	6
4.1. Homology Modeling	6
4.2. Pharmacophore Modeling	10
4.3. Molecular Docking and Dynamics Simulations	21
4.4. Fragment-Based Drug Discovery	32
4.5. De Novo Drug Discovery	37
4.5. Virtual Screening (VS) and Virtual High-throughput screening (vHTS)	38
5. CHALLENGES IN SBDD FOR SARS-COV-2	50
CONCLUSION	52
CONSENT FOR PUBLICATION	52
CONFLICT OF INTEREST	52
ACKNOWLEDGMENTS	53
REFERENCES	53
CHAPTER 2 POTENTIAL ANTIVIRAL MEDICINAL PLANTS AGAINST NOVEL SARS-COV-2 AND COVID-19 OUTBREAK	62
<i>Nazim Sekeroglu and Sevgi Gezici</i>	
1. INTRODUCTION	63
2. MEDICINAL PLANT-BASED ANTIVIRAL THERAPEUTICS	65
2.1. Rockrose (<i>Cistus</i> spp.)	71
2.2. Lemon balm (<i>Melissa Officinalis</i> L.)	72
2.3. Rosemary (<i>Rosmarinus Officinalis</i> L.)	74
2.4. Olive leaf (<i>Olea Europea</i> L.)	77
2.5. Thyme Species (<i>Origanum, Thymus & Thymbra</i>)	79
2.6. Licorice Root (<i>Glycyrrhiza Glabra</i> L.)	81
2.7. Other Antiviral Medicinal Plants	85
CONCLUSION AND FUTURE DIRECTIONS	86
LIST OF ABBREVIATIONS	86
CONSENT FOR PUBLICATION	87
CONFLICT OF INTEREST	87
ACKNOWLEDGEMENT	87
REFERENCES	87
CHAPTER 3 INFECTIONS CAUSED BY SARS: MAIN CHARACTERISTICS, TARGETS AND INHIBITORS	95
<i>Herbert Igor Rodrigues de Medeiros, Gabriela Cristina Soares Rodrigues, Mayara dos, Santos Maia, Marcus Tullius Scotti and Luciana Scotti</i>	
1. INTRODUCTION	95
2. ORIGIN AND EPIDEMIOLOGY	97

3. SARS PATHOGENESIS	99
4. TAXONOMY	101
5. MAIN TARGETS OF SARS-COV AND SARS-COV-2	103
5.1. Glycoprotein Spike (S)	104
5.2. Membrane Protein (M)	107
5.3. Envelope Protein (E)	108
5.4. Nucleocapsid Protein (N)	109
5.5. 3-chymotrypsin-like Cysteine Protease (3CLpro)	111
5.6. Angiotensin Converting Enzyme (ACE)-2	113
6. DRUGS AND INHIBITORS AGAINST SARS	114
CONCLUSION	126
LIST OF ABBREVIATIONS	127
CONSENT FOR PUBLICATION	128
CONFLICT OF INTEREST	128
ACKNOWLEDGEMENT	128
REFERENCES	128
CHAPTER 4 NATURAL SOURCED TRADITIONAL INDIAN AND CHINESE MEDICINES TO COMBAT COVID-19	138
<i>Mayank Kumar Khede, Anil Kumar Saxena and Sisir Nandi</i>	
1. INTRODUCTION TO INDIAN AND CHINESE TRADITIONAL MEDICINE	139
2. TRADITIONAL DRUGS AND NATURAL SOURCED FORMULATION FOR TREATMENT OF COVID-19	142
2.1. Traditional Indian Medicines (TIM) to Combat COVID-19	143
2.2. Traditional Chinese Medicine (TCM) To Combat COVID-19	150
CONCLUSION	152
CONSENT FOR PUBLICATION	152
CONFLICT OF INTEREST	152
ACKNOWLEDGEMENT	152
REFERENCES	152
CHAPTER 5 PEPTIDOMIMETIC AND PEPTIDE-DERIVED AGAINST 3CLPRO FROM CORONAVIRUSES	158
<i>Paulo Fernando da Silva Santos-Júnior, João Xavier de Araújo-Júnior and Edeildo Ferreira da Silva-Júnior</i>	
1. INTRODUCTION	158
2. CHEMISTRY ASPECTS OF PEPTIDOMIMETICS	160
3. BIOCHEMISTRY ASPECTS AND MOLECULAR HOMOLOGY OF 3CLPRO FROM MERS-COV, SARS-COV, AND SARS-COV-2	162
3.1. Structure, Function, and Druggability of 3CLpro from Coronaviruses	162
3.2. Catalytic Site of 3CLpro from Coronaviruses	162
4. CORONAVIRUSES 3CLPRO AND THEIR INHIBITORS	163
4.1. Warhead Groups	164
4.2. Peptidomimetics Containing Michael Acceptors as Warhead Groups	166
4.3. Peptidomimetics Containing Aldehydes as Warhead Groups	168
4.4. Peptidomimetics Containing Keto Groups as Warheads	171
4.4.1. Fluoromethyl Ketone Group	171
4.4.2. 1,4-Peptidomimetics Containing Phthalazinediones as Warhead Groups	173
4.4.3. Peptidomimetics Containing Benzothiazolones/thiazolones as Warhead Groups	175
4.4.4. Peptidomimetics Containing α -ketoamides as Warhead Groups	176
4.4.5. Peptidomimetics Containing Nitroanilides as Warhead Groups	177
4.5. Peptidomimetics Containing Nitriles as Warhead Groups	177

4.6. Peptidomimetics Containing Aza-epoxides and Aziridines as Warhead Groups	178
5. DRUG REPURPOSING FOR PEPTIDOMIMETICS	179
6. FINAL CONSIDERATIONS AND FUTURE OUTLOOK	180
CONSENT FOR PUBLICATION	181
CONFLICT OF INTEREST	181
ACKNOWLEDGEMENTS	181
REFERENCES	181
SUBJECT INDEX	18;

PREFACE

The new coronavirus (2019-nCoV) is part of the group of viruses in a format similar to a crown (Corona), more specifically belonging to the species Betacoronavirus, such as Middle East respiratory syndrome coronavirus (MERS-CoV) and acute respiratory syndrome (SARS). The outbreak was first reported in Wuhan, China, in December 2019, where several cases similar to pneumonia and SARS started to appear with symptoms of fever, cough, and severe respiratory difficulties [1 - 4]. Its origin is still unknown. Some works suggest mutations of the virus in bats or snakes, animals commercialized in the Wuhan market, which have infected humans. The homology similar to the 2019 - nCoV than to your Sequences of Bat SARS-like coronavirus supports the hypothesis that the transmission chain began from the bat and reached the human [5, 6]. It was what happened to the infectious agent that caused COVID-19.

The improvement of drug discovery techniques is fundamental in searching for new therapies that could be selective and effective to combat SARS-CoV-2. Drug discovery approaches are based on ligands (Ligand-Based Drug Design - LBDD) or structures (Structure-Based Drug Discovery - SBDD). Concerning SBDD, it is the main and most evolved technique used for discovering new drugs. The application of SBDD techniques has been improved the pharmacological arsenal against diverse diseases, which allowed to discover innovative treatments, such as inhibitors of HIV-1 proteases. In chapter I, main SBDD techniques (*i.e.*, homology modeling; molecular dynamics and docking; de novo drug discovery; pharmacophore modeling; fragment-based drug discovery; and virtual high-throughput screenings) applied to discover new hit compounds SARS-CoV-2 (COVID-19) will be discussed in detail.

Medicinal plants with a wide range of bioactive compounds, which are exhibiting antiviral activities, are able to provide possible benefits as a preventive and treatment for COVID-19. Rockrose (*Cistus* spp.), lemon balm (*Melissa officinalis* L.), rosemary (*Rosmarinus officinalis* L.), licorice root (*Glycyrrhiza glabra* L.), olive leaf (*Olea europea* L.), peppermint (*Mentha piperita* L.), basil (*Ocimum bacilicum* L.), sumac (*Rhus coriaria* L.) and different species of thyme (*Origanum*, *Thymus*, and *Thymbra*) are important medicinal plants having antiviral activities. Chapter II provides an overview of published scientific information on the development of plant-based antiviral therapeutic agents based on the extensive literature survey. Researchers from all over the world are dedicating themselves to several studies in an attempt to find the best treatment and prevention against the coronavirus. Chapter III addresses the main characteristics of SARS, the main targets and drugs that have achieved excellent results in clinical trials.

With increasing COVID-19 cases globally, it would be too difficult to provide proper treatment even for the severe cases in hospitals. Therefore, the general public is advised to wear the mask, maintain social distancing and use sanitizers. The COVID-19 mild infected patients may be isolated at home and can be taken care of by natural medicines. In chapter IV, an attempt has been made to repurpose all potential natural drugs and natural Ayurvedic formulations that may be beneficial to combat viruses like the SARS-CoV-2 due to their antiviral and immune-modulator properties available under Indian traditional medicine and Chinese traditional medicine system for the effective treatment or prevention of COVID-19.

Peptidomimetics have emerged as a potential class for designing new effective drugs against COVID-19, in addition to lopinavir/ritonavir, in which these drugs are currently being investigated in clinical trials. In chapter V, the authors describe peptidomimetic and peptide-

derived inhibitors of 3CL^{pro} from SARS-CoV-2, and also SARS- and MERS-CoV viruses, summarizing all relevant studies based on warhead groups utilization and SAR analysis for all of them to contribute to the development of compounds more selective, effective, and low-costs to combat these emerging viruses.

Luciana Scotti

&

Marcus T. Scotti

Laboratory of Cheminformatics
Program of Natural and Synthetic Bioactive Products (PgPNSB)
Health Sciences Center, Federal University of Paraíba
João Pessoa-PB, Brazil

REFERENCES

- [1] Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi M. The 2019-new coronavirus epidemic: Evidence for virus evolution. *J Med Virol* 2020; 92(4): 455-9. [<http://dx.doi.org/10.1002/jmv.25688>] [PMID: 31994738]
- [2] Zaher NH, Mostafa MI, Altaher AY. Design, synthesis and molecular docking of novel triazole derivatives as potential CoV helicase inhibitors. *Acta Pharm* 2020; 70(2): 145-59. [<http://dx.doi.org/10.2478/acph-2020-0024>] [PMID: 31955138]
- [3] Phan T. Novel coronavirus: From discovery to clinical diagnostics. *Infect Genet Evol* 2020; 79: 104211. [<http://dx.doi.org/10.1016/j.meegid.2020.104211>] [PMID: 32007627]
- [4] Li G, Fan Y, Lai Y, *et al.* Coronavirus infections and immune responses. *J Med Virol* 2020; 92(4): 424-32. [<http://dx.doi.org/10.1002/jmv.25685>] [PMID: 31981224]
- [5] Mahase E. Coronavirus: doctor who faced backlash from police after warning of outbreak dies. *Bmj-British Medical Journal* 2020; 368 [<http://dx.doi.org/10.1136/bmj.m528>]
- [6] Mowbray H. In Beijing, coronavirus 2019-nCoV has created a siege mentality. *Bmj-British Medical Journal* 2020. [<http://dx.doi.org/10.1136/bmj.m516>]
- [7] York A. Novel coronavirus takes flight from bats? *Nat Rev Microbiol* 2020; 18(4): 191. [<http://dx.doi.org/10.1038/s41579-020-0336-9>] [PMID: 32051570]

List of Contributors

- Anil Kumar Saxena** Global Institute of Pharmaceutical Education and Research, Kashipur-244713, Uttarakhand, India
- Edeildo Ferreira da Silva-Júnior** Chemistry and Biotechnology Institute, Federal University of Alagoas, Maceió, Brazil
Laboratory of Medicinal Chemistry, Pharmaceutical Sciences Institute, Federal University of Alagoas, Maceió, Brazil
- Herbert Igor Rodrigues de Medeiros** Laboratory of Cheminformatics, Program of Natural and Synthetic Bioactive Products (PgPNSB), Health Sciences Center, Federal University of Paraíba, João Pessoa-PB, Brazil
- Igor José dos Santos Nascimento** Chemistry and Biotechnology Institute, Federal University of Alagoas, Maceió, Brazil
- João Xavier de Araújo-Júnior** Laboratory of Medicinal Chemistry, Pharmaceutical Sciences Institute, Federal University of Alagoas, Maceió, Brazil
- Luciana Scotti** Laboratory of Cheminformatics, Program of Natural and Synthetic Bioactive Products (PgPNSB), Health Sciences Center, Federal University of Paraíba, João Pessoa-PB, Brazil
- Marcus Tullius Scotti** Laboratory of Cheminformatics, Program of Natural and Synthetic Bioactive Products (PgPNSB), Health Sciences Center, Federal University of Paraíba, João Pessoa-PB, Brazil
- Mayank Kumar Khede** Care Support and Treatment Division, Chhattishgarh State Aids Control Society, Department of Health and Family Welfare, Chhattisgarh, India
- Mayara dos Santos Maia** Laboratory of Cheminformatics, Program of Natural and Synthetic Bioactive Products (PgPNSB), Health Sciences Center, Federal University of Paraíba, João Pessoa-PB, Brazil
- Nazim Sekeroglu** Department of Horticulture, Faculty of Agriculture, Kilis 7 Aralik University, 79000 Kilis, Turkey
Advanced Technology Application and Research Center (ATARC), Kilis 7 Aralik University, 79000 Kilis, Turkey
- Paulo Fernando da Silva Santos-Júnior** Chemistry and Biotechnology Institute, Federal University of Alagoas, Maceió, Brazil
- Sevgi Gezici** Advanced Technology Application and Research Center (ATARC), Kilis 7 Aralik University, 79000 Kilis, Turkey
Department of Molecular Biology and Genetics, Faculty of Science and Literature, Kilis 7 Aralik University, 79000 Kilis, Turkey
- Sisir Nandi** Global Institute of Pharmaceutical Education and Research, Kashipur-244713, Uttarakhand, India
- Thiago Mendonça de Aquino** Chemistry and Biotechnology Institute, Federal University of Alagoas, Maceió, Brazil

CHAPTER 1

Structure-Based Drug Discovery Approaches Applied to SARS-CoV-2 (COVID-19)

Igor José dos Santos Nascimento¹, Thiago Mendonça de Aquino¹ and Edeildo Ferreira da Silva-Júnior^{1,2,*}

¹ Chemistry and Biotechnology Institute, Federal University of Alagoas, Maceió, Brazil

² Laboratory of Medicinal Chemistry, Pharmaceutical Sciences Institute, Federal University of Alagoas, Maceió, Brazil

Abstract: Viral diseases have caused millions of deaths around the world. In the past, health organizations and pharmaceutical industries have neglected these diseases for years, mainly because they affected a small geographic population. In contrast, since 2016, several viral outbreaks have been reported worldwide, such as those caused by Ebola, Zika, and SARS-CoV2 (COVID-19). Thus, these have received more attention, leading to increased efforts to search for new antiviral drugs. The SARS-CoV-2 pandemic, already responsible for more than 1,254,567 deaths worldwide, is the greatest example of a virus that has always been present in our society, responsible for small outbreaks in Asian and Arabic countries in 2004 and 2012. But, investments in research to identify/discover new drugs and vaccines were only intensified in 2020, in which only the remdesivir (an FDA-approved drug) was developed to address COVID-19 until today. Nonetheless, it has been used in hospitals in the United States and Japan, in emergency cases. Indeed, it justifies greater investments in discovering new alternatives that could save thousands of people. In this context, improving drug discovery techniques is fundamental in searching for new therapies that could be selective and effective to combat SARS-CoV-2. Drug discovery approaches are based on ligands (Ligand-Based Drug Design - LBDD) or structures (Structure-Based Drug Discovery - SBDD). Concerning SBDD, it is the main and most evolved technique used for discovering new drugs. The application of SBDD techniques has improved the pharmacological arsenal against diverse diseases, which allowed the discovery of innovative treatments, such as inhibitors of HIV-1 proteases. In this chapter, main SBDD techniques (*i.e.* homology modeling; molecular dynamics and docking; *de novo* drug discovery; pharmacophore modeling; fragment-based drug discovery; and virtual high-throughput screenings) applied to discover new *hit* compounds SARS-CoV-2 (COVID-19) will be discussed in details.

* **Corresponding author Edeildo Ferreira da Silva-Júnior:** Chemistry and Biotechnology Institute, Federal University of Alagoas, Maceió, Brazil and Laboratory of Medicinal Chemistry, Pharmaceutical Sciences Institute, Federal University of Alagoas, Maceió, Brazil; Tel: +55-87-9-9610-8311; E-mail: edeildo.junior@iqb.ufal.br

Keywords: Drug discovery, Dynamics simulations, Molecular modeling, SARS-CoV-2, Structure-Based Drug Discovery, TMRSS2, Virtual screening.

1. INTRODUCTION

On December 31st, 2019, an outbreak of pneumonia was reported caused by an unknown etiologic agent in Wuhan, a province of Hubei in China. Thus, with the sporadic number of cases, on January 9th, 2020, the new coronavirus was recognized as the causative agent by the Chinese Center for Disease Control and Prevention (CDC). When it started spreading at an alarming pace to other countries in the world, the new coronavirus (SARS-CoV-2, or COVID-19) was declared a pandemic by the world health organization (WHO) on March 11th, 2020 [1 - 3].

Since its discovery, SARS-CoV-2 has been responsible for several victims worldwide. To date (09/11/2020), there are already 50,266,033 confirmed cases with 1,254,567 deaths [4]. The main symptoms are fever, cough, fatigue, myalgia, and dyspnea. Its transmission occurs mainly through coughing, sneezing, and respiratory droplets [5]. These alarming statistics make research groups from around the world focus on discovering new therapies against this pandemic virus [6]. Advances in drug developments resulted in the repurposing of remdesivir in the United States. However, this drug still does not show the best effectiveness. So, a molecule that could be effective in eliminating SARS-CoV2 from the body is an unmet needed [6, 7].

Currently, biological targets guide the process of discovering new drugs. Then, the structure of a macromolecule is fundamental for this process [8]. Such structures provide valuable information on mechanisms of action and their correlation with biological activity [9]. In addition, information about the biological target and the availability of three-dimensional structures for these therapeutically attractive targets have resulted in several advances in the identification of inhibitors, as well as potential binding sites, contributing to the basis of structure-based drug discovery strategies (SBDD) [10].

In addition, *in silico* methods are increasingly gaining more visibility in the drug development field. These methods are used in SBDD and are related to higher chances of success with less financial cost and less time-consuming [11, 12].

In this context, this chapter will be addressed to the main SBDD techniques (homology modeling; molecular docking and dynamic; pharmacophore modeling; virtual screening and virtual high-throughput screening; fragment-based drug design; and *de novo* drug design) applied for the discovery of new promising compounds against SARS-CoV2.

2. CORONAVIRUSES: HISTORY AND STRUCTURE

Coronaviridae is a family of several groups of viruses responsible for the infection of both animals and humans. From this family, there are seven viruses that can infect humans, being: Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV); Middle East Respiratory Syndrome Coronavirus (MERS-CoV); Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2); HCoV-OC43; HCoV-KHU1; HCoV-NL63; HCoV-229E [13]. Among these, the first three belong to the genus *Betacoronavirus*, and all of them display high potential for mutability, leading to plasticity and genetic variability, which contributes to their adaptation to different types of hosts [13, 14].

The first discovery of SARS-CoV was around the 1960s [15]. This pathogen is related to flu-like symptoms. However, its progress generates respiratory failure and, in many cases, death since it presents a higher mortality rate [16]. The SARS-CoV is a virus from animal reservoirs (in this case, bats) that can spread to other animals and humans, initially reported in Guangdong (China), in 2002 [16 - 18]. One year later, it spread to Asia and America, affecting 26 nations and causing 8,000 deaths. After its control, other reports were associated with laboratory accidents or transmission from animals to humans [16].

Concerning MERS-CoV, the main reservoir is dromedary camels and bats. These pathogens can infect bat cells through the receptor dipeptidyl peptidase-4 (DPP4), which is similar to the human receptor. The MERS-CoV exhibited widespread exposure in the Middle East and North, as well as in East Africa [17]. This disease was initially identified in 2012, in Saudi Arabia, and it has spread to about 20 countries. Since then, MERS-CoV has been detected in Europe, the Gulf region, and Korea. Since 2016, it is estimated that were infected approximately 1,638 people, of which around 35% were fatal victims [16].

As mentioned in the introduction, a new CoV variant was detected in Wuhan, China (December 2019), giving rise to one of the most significant outbreaks of unknown viral pneumonia. The new SARS-CoV (SARS-CoV-2) is more genetically similar to the SARS-CoV than MERS-CoV. Thus, it could be used information from SARS- and also MERS-CoV to discover new therapies [19, 20].

Deeming the knowledge about the structure and function of the virus, it is possible to model drugs with a focus on each target. In this context, the structure of SARS-CoV-2 is composed of structural and non-structural proteins, being used frequently for the design of new inhibitors. The structural proteins are spike (S) glycoprotein, membrane (M), envelope (E), and nucleocapsid (N) proteins. Among these, S protein is one of the most promising targets in drug discovery for SARS-CoV-2. This protein is related to viral entry by recognition of the

Potential Antiviral Medicinal Plants against Novel SARS-CoV-2 and COVID-19 Outbreak

Nazim Sekeroglu^{1,2,*} and Sevgi Gezici^{2,3}

¹ Gaziantep University, Faculty of Science and Literature, Department of Biology, Gaziantep 27310, Turkey

² Gaziantep University, Faculty of Medicine, Department of Medical Biology, Gaziantep 27310, Turkey

³ Department of Molecular Biology and Genetics, Faculty of Science and Literature, Kilis 7 Aralik University, 79000 Kilis, Turkey

Abstract: Considering the significant worldwide threat of the Novel Corona Virus Disease 2019 (COVID-19), it is urgently needed to develop efficient prevention and treatment approaches in order to reduce the prevalence rate and mortality of the disease. Even though numerous experimental and clinical studies have been currently conducted for development of drug and vaccine throughout the world, and some partially effective vaccines and chemical drugs have been developed against COVID-19. Herbal and dietary plants, including fruits, vegetables, herbs, spices, cereals, and edible tubers/roots, can play a significant role in enhancing the immune system and how to increase our defense barriers against virus-related diseases. Accordingly, medicinal plants with a wide range of bioactive compounds, which exhibit remarkable antiviral activities, can be used as a preventive treatment and cure for COVID-19. In order to combat SARS-CoV-2, rockrose (*Cistus* spp.), lemon balm (*Melissa officinalis* L.), rosemary (*Rosmarinus officinalis* L.), licorice root (*Glycyrrhiza glabra* L.), olive leaf (*Olea europaea* L.), peppermint (*Mentha piperita* L.), basil (*Ocimum bacilicum* L.), sumac (*Rhus coriaria* L.) and different species of thyme (*Origanum*, *Thymus* and *Thymbra*) are important medicinal plants that exhibit valuable antiviral activities. Since medicinal and aromatic plants are a worldwide hot topic, the aim of the current review was to provide an overview of the development of plant-based anti-coronavirus agents to the researchers based on an extensive literature survey.

Keywords: Antiviral, Bioactive compounds, *Cistus* spp., Coronavirus, COVID-19, Immune system, Lemon balm, Licorice root, Medicinal plants, *Melissa officinalis* L., *Ocimum bacilicum* L., Olive leaf, Outbreak, Peppermint, Pharmaceutical industry, Phytochemicals, *Rhus coriaria* L., Rockrose, Rosemary, Therapeutics.

* Corresponding author Nazim Sekeroglu: Department of Horticulture, Faculty of Agriculture, Kilis 7 Aralik University, Postal Code 79000 Kilis, Turkey; Fax: +90 (342) 360 1013; Tel: +90 (342) 360 1200 - 1922; E-mails: nazimsekeroglu@gantep.edu.tr, nsekeroglu@gmail.com

1. INTRODUCTION

Throughout history, pandemics of large-scale outbreaks of infectious diseases such as Cholera, Ebola, Bubonic Plague, AIDS (acquired immunodeficiency syndrome), Influenza, SARS (severe acute respiratory syndrome), MERS (Middle East Respiratory Syndrome), and currently COVID-19 (new type coronavirus, causative agent 2019-nCoV or SARS-CoV-2) have had a major impact worldwide. The Corona Virus Disease 2019 (COVID-19) has had similar outbreaks to other viral diseases because of its global spread, social and economic response, however, the recent coronavirus outbreak is different from other occurrences. It has different biological properties, cell surface proteins, and mechanisms of infection [1 - 4].

Coronaviruses (CoVs) belong to the family of Coronaviridae, Arteriviridae, Roniviridae and Mesoniviridae families. Of which, Coronaviridae is the largest family and includes the subfamily of Coronavirinae, which is now classified into four main genera including alpha (α)-coronavirus, beta (β)-coronavirus, gamma (γ)-coronavirus and delta (δ)-coronavirus, according to the 10th report on virus taxonomy from the International Committee on Taxonomy of Viruses (ICTV). α -coronaviruses and β -coronaviruses infect a variety of host cells and can cause life-threatening pneumonia in humans and some animals such as feline, porcine, canine, mice, bovine, bat and rodent, while γ -coronavirus and δ -coronavirus are specific of birds, but some of them can also infect other organisms [4 - 6].

CoV is an enveloped virus group that carries single-strand RNA (ribonucleic acid) genome, capable of infecting humans and a wide variety of animal species. This group of viruses, especially causing upper respiratory infections, lead symptoms that present with a sore throat, dry cough, runny nose, weakness, and fatigue. In coronavirus infections, the symptoms occur in the form of colds or flu; the virus infects the ciliated epithelial cells in the nasopharynx through the aminopeptidase N receptor or sialic acid receptors and leads to the development of damage to the epithelial cells as the virus multiplies. In addition, chemokines and interleukins released from the cells cause the development of local illnesses in the patients. In the following process, the virus can pass to pneumocytes, blood, urine (up to 2 months), and in some cases to feces [3, 7, 8].

Based on the ICTV, FECV (Feline Enteric Coronavirus) and FIPV (Feline Infectious Peritonitis Virus), the porcine TGEV (Transmissible Gastro- Enteritis Virus), Porcine PEDV (Epidemic Diarrhea Virus), PRCoV (Porcine Respiratory Coronavirus), CCoV (Canina Coronavirus), and human coronaviruses (HCoV-229E and HCoVNL63) are of α -coronaviruses. Betacoronaviruses also compromise Murine coronavirus (MHV) and Bovine Coronavirus (BCoV), and

human coronaviruses (HCoV-OC43, HCoV-HKU1, SARS-CoV, MERS-CoV, and SARS-CoV-2). Interestingly, recent studies have shown that the new human CoV, namely SARS-CoV-2, shares high genome sequence similarity (almost 79.5%) with SARS-CoV, and similar to SARS-CoV, the new human CoV recognizes ACE2 (angiotensin-converting enzyme 2) cellular receptor to enter host cells. In addition to that, it has a similar genomic structure as SARS-CoV and MERS-CoV [2, 9 - 11].

Even though the history of CoVs began in the 1940's, the first human CoVs subsequently named as (i) human CoV 229E (HCoV-229E) and (ii) HCoV-OC43, were reported in the 1960's. After that, the virologist tried to identify the general structure of CoVs, as well as replication and pathogenesis. The studies among the virologist provided to the discovery of other new human coronaviruses such as (iii) HCoV- Hong Kong University 1 (HKU1), (iv) HCoV-NL63, (v) severe acute respiratory syndrome (SARS)-CoV and (vi) the Middle East respiratory syndrome (MERS)-CoV [2, 9, 12]. Among these coronaviruses, SARS-CoV was identified as a global outbreak in 2003, and it had affected 8422 people in 32 countries, with a mortality rate of 10-15% [3, 13]. Then, almost after ten years, another highly pathogenic coronavirus MERS-CoV epidemic emerged in Middle Eastern countries in 2013. Although the major MERS-CoV pandemic has happened in the Republic of Korea, it was observed worldwide at any age of people with a fatality rate of 39% [12, 14]. Following this outbreak, the novel coronavirus outbreak, namely 2019-nCoV or COVID-19 emerged in Wuhan State, Hubei Province, China, in December 2019. It has spread to many countries and territories, United States (US), Spain, Italy, France, Germany, the United Kingdom, China, Iran, Turkey, Belgium and Netherlands are among the hardest hit countries. Since, it has infected many people and caused a high mortality rate in a short period, the World Health Organization (WHO) has declared the outbreak of the new coronavirus as a pandemic. As of 19 November 2021, more than 255,324,963 confirmed cases of COVID-19 have been reported in more than 180 countries and territories, resulting in approximately 5,127,696 deaths all around the world [15, 16]. Moreover, the number of infected patients with COVID-19 and death from this virus are alarmingly increasing day by day. Due to its rapid infection ability from person to person and high mortality rate, it has become vital to find efficient and accurate therapy strategies to urgently combat this disaster [17, 18]. Thus, scientists have been racing to understand the different coronavirus diseases in order to discover possible therapy strategies including drugs, therapeutic antibodies, cytokines, nucleic acid-based therapy, vaccines to treat and prevent coronavirus infections. Among the given strategies, researching effective antiviral drugs, which may be appropriate to cure the COVID-19, have apparently been the most certain option for immediate treatment. Nevertheless, no specific drug has been studied or made available for COVID-19 cases and clinical trials, as well as

CHAPTER 3**Infections Caused by SARS: Main Characteristics, Targets and Inhibitors****Herbert Igor Rodrigues de Medeiros¹, Gabriela Cristina Soares Rodrigues¹, Mayara dos Santos Maia¹, Marcus Tullius Scotti¹ and Luciana Scotti^{1,*}**¹ *Laboratory of Cheminformatics, Program of Natural and Synthetic Bioactive Products (PgPNSB), Health Sciences Center, Federal University of Paraíba, João Pessoa-PB, Brazil*

Abstract: SARS-coronavirus (SARS-CoV) originated in China from 2002 to 2003 and caused a global outbreak with 8098 cases and 774 confirmed deaths. More than 15 years later, in less than a year, the new coronavirus (2019-nCoV) has infected more than 44 million people and killed more than 1 million. The COVID-19 pandemic has brought serious consequences for several countries and a worldwide alert about coronaviruses. Severe acute respiratory syndrome (SARS) is an emerging infectious viral disease characterized by severe clinical manifestations of the lower respiratory tract that lead to severe lung damage and the spread of the virus to several other organs. Phylogenetic analyzes demonstrate that SARS-CoV-2 shares a 79% identity with SARS-CoV, and just as there was no effective treatment against SARS-CoV, it does not yet exist against SARS-CoV-2. However, researchers from all over the world are dedicating themselves to several studies in an attempt to find the best treatment and prevention against the coronavirus. Thus, this book chapter addresses the main characteristics of SARS, the main targets and drugs that have achieved excellent results in clinical trials.

Keywords: Drugs, SARS, SARS-CoV, Sar-CoV-2, Target.

1. INTRODUCTION

Coronaviruses (CoVs) are RNA viruses that cause respiratory and enteric diseases with variable pathogenicity in humans and animals. All CoVs are known to infect humans are zoonotic, or of animal origin, and many believe they originate from host bats [1, 2]. Due to the large size of the genome (the largest non-segmented RNA viral genome), single-stranded and positive sense of about 26–32 kb in size, frequent recombination and high genomic plasticity, CoVs are prone to transmission between species and are able to adapt quickly to new hosts [2, 3].

* **Corresponding author Luciana Scotti:** Laboratory of Cheminformatics, Program of Natural and Synthetic Bioactive Products (PgPNSB), Health Sciences Center, Federal University of Paraíba, João Pessoa-PB, Brazil; Tel: +5583996245075; E-mail: luciana.scotti@gmail.com

Severe acute respiratory syndrome (SARS), which emerged as a pandemic in 2002 and 2003, was caused by Severe acute respiratory syndrome coronavirus (SARS-CoV), a virus previously unknown [4, 5]. This virus was first isolated in 2003 from samples from three SARS patients. According to the World Health Organization (WHO), SARS has infected more than 8,000 people and caused at least 813 deaths [6, 7].

SARS-CoV has been identified as a clinical entity in which patients have a fever, dry cough, dyspnoea, headache and hypoxemia. Typical laboratory findings are lymphopenia and slightly elevated aminotransferase levels. Death can result from progressive respiratory failure due to alveolar damage caused by an infectious agent transmitted from human to human [8].

The pathological features available for SARS-CoV infections were mainly obtained at autopsies. The predominant visceral macroscopic were changes in fatal cases of SARS - CoV mainly in edematous lungs with increased gross weight and multiple areas of congestion, increased lymph nodes in the pulmonary hiluses and in the abdominal cavity, as well as decreased spleen size and reduced spleen weight [9, 10].

A large number of SARS-CoV particles and genomic sequences have been detected in circulating lymphocytes, monocytes and lymphoid tissues, as well as in epithelial cells of the respiratory tract, intestinal mucosa, epithelium of renal distal tubules, neurons in the brain and macrophages residing in tissues that reside in different organs [11]. The therapeutic agent effective against SARS was unavailable at the time of the initial outbreak. Fortunately, SARS has been successfully contained, and no SARS outbreaks have been reported since 2004 [4].

An outbreak of pneumonia with unknown cause was reported in Wuhan, Hubei province, China, in December 2019, associated with the Huanan Seafood Wholesale Market [12]. The causative agent of the outbreak was identified by the WHO as the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), producing the disease called coronavirus disease-2019 (COVID-19) (13). SARS-CoV-2 shares 96.3%, 89% and 82% of nucleotide similarity with the bat CoV RaTG13, SARS-like CoV ZXC21 and SARS-CoV, respectively, which confirms its zoonotic origin, based on the analysis phylogenetics [13 - 15]. Human-t-human transmission has been confirmed even in asymptomatic carriers.

The virus has spread to at least 219 countries and territories and in October 2020, the global epidemiological situation is over 42 million cases and 1.1 million deaths reported globally, with massive global increases in the number of daily

cases with more 2.8 million new cases and nearly 40,000 new deaths reported in the past few days [16].

2. ORIGIN AND EPIDEMIOLOGY

At the beginning of the SARS epidemic, most patients had animal exposure rates before developing the disease. Subsequently, the causative agent of SARS was identified, SARS-CoV and / or anti-SARS-CoV antibodies were found in palm civets (*Paguma larvata*) and animals handled in a market [17 - 20]. However, research using breeding and wild civets revealed that the SARS-CoV strains found in market civets were passed on to them by other animals [21, 22].

Research has also identified the coronavirus in zoonotic reservoirs, including horseshoe bats (genus *Rhinolophus*), Himalayan palm civets (*Paguma larvata*) and raccoon dogs (*Nyctereutes procyonoides*), and determined that the virus that infected human hosts is from southern China, in Guangdong province [2, 7 - 9].

Subsequent studies have shown that wild horseshoe bats (Family *Rhinolophidae*), which can also be found in LAM in China and served in some Chinese restaurants in Guangdong, China, have detectable levels of antibodies against SARS-CoV, suggesting a bat origin for the SARS-CoV [22].

The evolutionary relationship between coronavirus and bats was proposed, in which the ancestor for SARS-CoV first spread to bats of the *Hipposideridae* family, then to *Rhinolophidae* and then to palm civets and, eventually, to humans [23].

In 2013, two new SARS-like CoVs were isolated from *Rhinolophus* bats in China, and these viruses showed a high relationship with SARS-CoV of all bat coronaviruses [24]. ORF8 analysis of SARS-identical CoVs in bats suggests that Chinese horseshoe bats are the natural reservoirs of SARS-CoV, these viruses are identified by a set of unique accessory open reading structures (Open Read Frame - ORFs) that are located between the M genes and N [25].

According to their antigenic and genetic characteristics, CoVs are classified into three groups. The main group of CoVs comprises Porcine Transmissible Gastroenteritis Virus (TGEV), Feline Coronavirus (FCoV), Canine Coronavirus (CCoV), HCoV-229E and Porcine Epidemic Diarrhea Virus (PEDV). The second group consists of murine hepatitis Virus (MHV), Bovine Coronavirus (BCoV), HCoV-OC43, Swine Hemagglutinating Encephalomyelitis Virus (HEV), Rat Coronavirus (RtCoV) and Equine Coronavirus (ECoV). The third group is formed by Avian Infectious Bronchitis Virus (IBV), Turkey Coronavirus (TCoV) and Coronavirus Pheasant [26]. This subfamily is formed by four genera,

Natural Sourced Traditional Indian and Chinese Medicines to Combat COVID-19

Mayank Kumar Khede¹, Anil Kumar Saxena^{2,*} and Sisir Nandi^{2,*}

¹ Care Support and Treatment Division, Chhattishgarh State Aids Control Society, Department of Health and Family Welfare, Chhattisgarh, India

² Global Institute of Pharmaceutical Education and Research, Kashipur-244713, Uttarakhand, India

Abstract: The corona virus disease (COVID-19) was started in Wuhan, China, in late 2019. It is caused by a novel strain of severe acute respiratory syndrome corona viruses (SARS-CoV-2) that has become pandemic on March 11, 2020 and endangered the existence of human beings on the earth as the infection has been spreading in mass population day by day within a few months with a high killing rate. The COVID-19 pandemic has pushed the modern health care system of developing and developed countries to their limits for its effective management and control since the drug discovery process is a long journey and challenging task and there is no specific small molecule chemotherapeutics to combat this novel coronavirus. Hence, the existence of human life is a great challenge. Mother Nature has played an important role to combat many pandemics that arrived in past centuries in absence of modern medicines. Nature has been a source of many natural drugs derived from plants' secondary metabolites which may be used to combat COVID-19. Natural sourced traditional Indian and Chinese medicines alternative therapy should be prioritized in combination with modern medicines to combat COVID-19. With rising COVID-19 cases globally, it would be too difficult to provide proper treatment even for the severe cases in hospitals. Therefore, the general public is advised to wear the mask, maintain social distancing, and use sanitizers. The COVID-19 mild infected patients may be isolated at home and can be taken care of by natural medicines. In this chapter, an attempt has been made to repurpose all potential natural drugs and natural Ayurvedic formulations that may be beneficial to combat viruses like the SARS-CoV-2, due to their antiviral and immune-modulator properties available under Indian traditional medicine and Chinese traditional medicine system for the effective treatment or prevention of COVID-19.

Keywords: COVID-19, Drug repurposing, Natural formulations, Traditional Chinese medicines (TCM), Traditional Indian medicines (TIM).

* **Corresponding author Anil Kumar Saxena and Sisir Nandi:** Global Institute of Pharmaceutical Education and Research, Kashipur-244713, India; Tel: +91 7500458478; E-mails: anilsak@gmail.com, sisir.iicb@gmail.com

Luciana Scotti and Marcus T. Scotti (Eds.)
All rights reserved-© 2022 Bentham Science Publishers

1. INTRODUCTION TO INDIAN AND CHINESE TRADITIONAL MEDICINE

In the current 21st century, when the whole world is fighting a tough and decisive battle against COVID-19 caused by a novel coronavirus, natural products and their derivatives have potential activities to combat this pandemic [1, 2]. Since the beginning of 2020, new anti COVID-19 drug discovery strategies based on natural products and traditional medicines are evolving as an alternative option till specific anti COVID-19 drugs and vaccines are introduced in the global market to eliminate novel coronavirus [3].

According to the World Health Organization (WHO), the traditional medicine system includes a diversity of health practices, approaches, knowledge, and beliefs that incorporates plant, animal, and/or mineral-based medicines, spiritual therapies, manual techniques, and exercises, which are applied singly or in combination to maintain well-being and to treat or prevent the illness [4]. India, one of the ancient civilizations of the world, has the oldest heritage of the traditional medicine system, nurtured between 2500 B.C and 500 BC. The Sanskrit meaning of Ayu is life and Veda is knowledge or science [5]. Medicinal plants play a major role and constitute the backbone of traditional medicine. The Indian materia medica includes about 2000 drugs that are derived from India's different traditional systems, hence, Indian medicinal plants and other traditional medicines can be considered as a new option to overcome the viral transmission of COVID 19 [6]. Similarly, Traditional Chinese medicine (TCM), is one of the oldest continuously surviving traditions. The TCM is a system of healing that developed in China about 3000 years ago and includes natural herbal medicines used for maintaining good health and treating diseases in Chinese communities and has been adopted recently by other countries worldwide. In the year 2020, the use of TCM has become very popular in China and other parts of the world due to its effective utilization in combating COVID-19 [7]. At this time, in the absence of any specific anti COVID drug, all countries, including India, have to join hands together to fight COVID-19 by practicing precautionary measures such as regular hand washing, wearing of masks, and social distancing to prevent the attack of COVID-19 infection. In this study, an effort has been made to review and enlist the antiviral drugs and formulation of natural origin available and reported in Indian and Chinese traditional systems to combat COVID-19.

In December 2019, the sudden emergence of novel coronavirus (2019-nCoV) was observed by the world. It has been erupted in China Wuhan, Hubei Province, and spread across China and beyond [8]. On January 30, 2020, the World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern (PHEIC) [9]. On February 12, 2020, WHO named the

disease caused by the novel coronavirus Coronavirus Disease 2019, (COVID-19) [10].

The 2019 novel coronavirus (2019-nCoV) or the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as it is now called [11] has its history began back in the late 1960s when virologist Tyrrell and Bynoe found that they could passage a virus named B814 obtained from the respiratory tract of an adult with a common cold [12]. As a leading virologist, Tyrrell worked with the human strains, and several animal viruses like bronchitis virus, hepatitis virus demonstrated their same morphology under an electron microscope [13, 14]. This new group of viruses was named “coronavirus”. Coronaviruses are enveloped positive-sense RNA viruses ranging from 60 nm to 140 nm in diameter with spike-like projections on their surface, giving them a crown-like appearance under the electron microscope; hence the name “coronavirus”. The main targets of the SARS-CoV-2 are spike, envelope, membrane, nucleocapsid, and viral genome, which are responsible for the virulence while diffusing into the host cell by binding the viral spike with the human ACE 2 receptor [15] (Fig. 1).




Fig. (1). Structure of novel coronavirus virion and its binding site in human body [15, 16].

Coronaviruses, having a total of 39 species under the broad realm of Riboviria, belong to the family Coronaviridae, suborder Cornidovirineae and order Nidovirales. Human coronavirus (HCoV-HKU1), SARS-CoV, SARS CoV-2, and Middle East respiratory syndrome coronavirus (MERS-CoV), belong to the betacoronavirus genus [16, 17] of them SARS CoV-2 is very dangerous because of its high killing rate of the human population, which directly hit the socioeconomic movement of the world.

Peptidomimetic and Peptide-Derived Against 3CL^{pro} from Coronaviruses

Paulo Fernando da Silva Santos-Júnior¹, João Xavier de Araújo-Júnior² and Edeildo Ferreira da Silva-Júnior^{1,2,*}

¹ Chemistry and Biotechnology Institute, Federal University of Alagoas, Maceió, Brazil

² Laboratory of Medicinal Chemistry, Pharmaceutical Sciences Institute, Federal University of Alagoas, Maceió, Brazil

Abstract: SARS-CoV-2 is an RNA virus responsible for causing pandemic COVID-19, which has taken on unprecedented proportions so far in global health and economic aspects. In this context, the search for effective drugs against SARS-CoV-2 has become a priority for the global scientific community, where the chymotrypsin-like picornavirus 3C-like protease (3CL^{pro}, which is also named as main protease (M^{pro}), or only 3C) is a promising druggable target since it is crucial for the process of viral replication. Several 3CL^{pro} inhibitors have been recently reported in the literature. Thus, peptidomimetics have emerged as a potential class for designing new effective drugs against COVID-19, in addition to lopinavir/ritonavir, in which these drugs are currently being investigated in clinical trials. In this chapter, we describe peptidomimetic and peptide-derived inhibitors of 3CL^{pro} from SARS-CoV-2, and also SARS- and MERS-CoV viruses, summarizing all relevant studies based on warhead groups utilization and SAR analysis for all of them in order to contribute to the development of compounds more selective, effective, and low-costs to combat these emerging viruses.

Keywords: 3CL^{pro} inhibitors, Drug Design, MERS-CoV, Peptidomimetics, SARS-CoV, SARS-CoV-2.

1. INTRODUCTION

Coronavirus (CoV) refers to enveloped viruses belonging to the family *Coronaviridae* (subfamily: *Coronavirinae*; order: *Nidovirales*), which is responsible for causing potential severe infectious processes in the human respiratory tract [1, 2].

* Corresponding author Edeildo Ferreira da Silva-Júnior: Chemistry and Biotechnology Institute, Federal University of Alagoas, Maceió, Brazil and Laboratory of Medicinal Chemistry, Pharmaceutical Sciences Institute, Federal University of Alagoas, Maceió, Brazil; Tel: +55-87-9-9610-8311; E-mail: edeildo.junior@iqb.ufal.br

Two serious epidemics were caused by CoV, being *Middle East Respiratory Syndrome-coronavirus* (MERS-CoV), Arabian Peninsula, causing a total of 740 deaths, and 2,123 cases, in 2014. Besides, *Severe Acute Respiratory Syndrome-coronavirus* (SARS-CoV) was responsible for infecting 8,500 individuals, leading to 800 deaths in Guangdong province of China, between 2002-2003 [3 - 5].

Recently declared a pandemic by WHO (March 11th, 2020), COVID-19 is caused by the SARS-CoV-2 (previously called 2019-nCoV) [6]. Initially, it was reported on December 8th, 2019, in Wuhan, Huabei, China [7 - 9], causing severe respiratory complications. So far, this new-CoV has infected more than 246 million individuals worldwide, causing more than 5 million deaths, up to November 3rd 2021 [10].

Even in the third outbreak caused by a coronavirus, there is still no approved treatment or selective antiviral agents to combat this virus, nor approved vaccines [11 - 14]. Thus, current therapy involves treating symptoms, as well as providing oxygenation to the affected individuals, in addition to protective methods to avoid viral transmissions, such as wearing masks, hand hygiene, and social distancing [15, 16].

Medicinal chemistry has concentrated strategies for the development of bioactive compounds against the new coronavirus targeting enzymes [17, 18], in special the chymotrypsin-like picornavirus 3C-like protease (3CL^{pro}, also called main protease (M^{pro}), or only 3C), which emerges as the main druggable target from SARS-, MERS-CoV, and SARS-CoV-2 [17 - 22].

This protease (corresponding to nsP5) is directly responsible for the cleavage of the pp1a and pp1ab proteins, thus exercising a primordial function for controlling the viral cycle of replication [23 - 25]. Moreover, the genome sequence of SARS-CoV-2 3CL^{pro} is closely similar to the same protein from SARS-CoV [26, 27].

The utilization of peptide-based drugs (also named peptidomimetics) has been widely related to the design of bioactive compounds since this chemical class is involved in several regulatory processes in the human organism [28, 29]. Furthermore, endogenous peptides tend to demonstrate a strong binding with enzymatically active sites [30, 31].

In this context, this chapter summarizes strategies for developing peptidomimetics against 3CL^{pro} from MERS-, SARS-CoV, and SARS-CoV-2. We aim to demonstrate some warhead groups used in the design of these inhibitors, as well as discuss SAR analysis involving the most promising compounds, thus providing valuable information to assist in the development of new anti-virus drugs against this global emergency.

2. CHEMISTRY ASPECTS OF PEPTIDOMIMETICS

Peptides are intrinsically related to several physiological mechanisms in humans, in order to promote regulation of functions in the immune, digestive, defense, reproductive, respiratory, circulatory systems, in addition to metabolism and reproduction. Thus, at least 60 peptides have been described in the literature for therapeutic use in different clinical stages, being reported as inhibitors against HIV protease, hepatitis C virus (HCV), antimicrobial, treatment of dry eye syndrome (DED), among other activities, as described in Fig. (1) [31 - 35].




Fig. (1). Peptide-based drugs and their biological applications.

In 2010, four peptide drugs were responsible for US\$ 1 billion in global sales, demonstrating the therapeutic potential from this drug design approach [36]. However, the peptide-based drug design still has a significant disadvantage in some pharmacokinetic aspects due to their high molecular mass can result in deficient absorption since there is no specific transport system for them. Also, these compounds present limited stability in toward proteolysis from the gastrointestinal system and serum [30, 33, 37].

SUBJECT INDEX

A

- Absorption 124
 ACE2 114
 downstream pathway 114
 protection 114
 Acid 10, 26, 31, 43, 63, 67, 68, 69, 73, 74, 75,
 76, 77, 78, 80, 81, 82, 83, 84, 85, 86,
 110, 113, 119, 149
 acetylsalicylic 83
 aglicone glycyrrhetic 82
 ascorbic 149
 caffeic 31, 74, 80
 carboxylic 75
 carnolic 77, 80
 chebulinic 43
 chrysophanic 113
 corosolic 26
 elenolic 78
 ellagic 149
 gallic 149
 glutamic 113
 glycyrrhizic 10, 26, 68, 82, 84, 85
 glycyrrhizinic 84
 lithospermic 43
 maslinic 26
 nucleic 110
 oleanolic 68, 69, 74, 75, 78, 119
 phenolic 73, 75
 pomolic 74
 protocatechuic 74
 Protocatechuic 81
 reolinolic 78
 ribonucleic 63
 rosemarinic 68, 76
 rosmarinic 67, 68, 73, 75, 80
 syringic 81
 ursolic 26, 70, 74, 75, 85, 86, 119
 vanilic 81
 Action 81, 118, 120, 149
 anti-proliferative 149
 antiviral 81, 118, 120
 Activity 39, 45, 73, 74, 75, 76, 81, 84, 85, 86,
 109, 111, 112, 114, 123, 148, 150, 160,
 161, 167, 169
 anti-HIV 75
 anti-HSV 76
 anti-IBV 85
 anti-inflammatory 144, 150
 broad-spectrum antiviral 112
 effective antiviral 123
 enzymatic 111, 113
 hemagglutinating 148
 virucidal 81
 Acute 101, 102, 149
 respiratory distress syndrome (ARDS) 101,
 149
 respiratory infections 102
 systemic inflammatory syndrome 101
 Addison's disease 82
 Adenoviruses 70, 85
 Agent 78, 146, 149
 anti-inflammatory 149
 hematinic 149
 Amino acids 107, 162
 histidine 162
 neutral 107
 Aminopeptidase 63
 Analysis 80, 96, 99, 101
 phylogenetic 99, 101
 spectroscopic 80
 phylogenetics 96
 Angiotensin converting enzyme (ACE) 113,
 114
 Anti-HIV peptidomimetic drugs 180
 Antiviral activity of glycyrrhizin and
 glycyrrhizic acid 82
 Artemisia kermanensis 77
 Arthritis 75, 82
 Assays 80, 113, 116, 121, 164, 169
 antiviral 169
 enzymatic 121
 kinetics 164
 Asthma 67, 82, 101, 147, 149, 150

ameliorates allergic 149
bronchial 67
Autoimmunity 101
Avian 67, 73, 97
 infectious bronchitis virus 97
 influenza virus (AIV) 67, 73
Ayurveda and traditional Chinese medicine
 143
Azithromycin 31, 83

B

Bacillus 72, 83
 cereus 72
 subtilis 72, 83
Binding 24, 83, 108, 111
 efficient membrane 108
 functional RNA 111
 host cell membrane 83
 protein-protein interactions 24
Biochemical processes 21
Bioisosterism technique 166, 167
Bovine 63, 70, 80, 85, 97
 coronavirus (BCoV) 63, 97
 viral diarrhoea virus (BVDV) 70, 80, 85
Bronchitis 82, 147, 149
Bronchitis virus 67, 69, 70, 85, 140
 infectious 67, 69, 70, 85
Bronchoscopy 100

C

Candida albicans 72
Canine 63, 70, 80, 81, 97
 coronavirus (CCoV) 63, 70, 80, 97
 distemper virus (CDV) 70, 80, 81
Cardiac diseases 146
Cardiopulmonary resuscitation 100
Cathepsins 106, 107
 lysosomal 107
Cellular signal 83, 84
 transduction mechanisms 83
 transmissions 84
Chemokine profiles 100

Chikungunya virus 69, 83
Chinese traditional medicine 139
Chlamydia pneumonia 72
Cistus 66, 71, 75
 albiflorus 71
 creticus 71
 sinensis 66, 75
CMK-based inhibitors 169
Combat 138, 143
 diseases 143
 viruses 138
Computer 5, 6, 10, 51
 aided drug design (CADD) 5, 6, 10
 technology 51
Coronavirus 62, 63, 64, 65, 66, 84, 95, 97, 98,
 102, 104, 105, 113, 114, 140, 158, 159
 infections 63, 64, 113
 outbreaks 63, 65
 related diseases 65
 related infections 84
COVID-19 infection 139, 143, 144, 148, 150,
 151
Crystallographic inhibitor 21
Curcuma Longa 146
Cyclooxygenase 108
Cysteine proteases 162, 178
Cytokine release syndrome (CRS) 101
Cytomegalovirus 69, 83

D

Dengue infections 66
Diarrhea 78, 99, 100, 101, 142, 147
Disease 1, 3, 62, 96, 97, 99, 101, 102, 139,
 140, 141, 150, 151
 epidemics 102
 respiratory 99, 150
Disorders 73, 145, 146
 metabolic 145
 nervous 73
 nervous stomach 73
Docking analysis 23, 40
Drug design 5, 38, 50, 111, 158, 160, 163, 167
 computer-aided 5

Subject Index

peptide-based 160
techniques 38, 167
Drug repurposing 9, 15, 28, 40, 138, 179
methods 40
virtual 15
Drugs 2, 9, 34, 40, 41, 50, 51, 52, 64, 65, 95,
112, 114, 121, 139, 148, 152, 160, 161
anti COVID-19 139
antimalarial 148
broad-spectrum 65
peptide 160
synthetic 161
Dysenteriae 84

E

Echovirus 69, 70, 81, 83
Effects 25, 72, 73, 77, 80, 84, 85, 148, 149
bronchodilatory 149
cytopathic 80
cytopathogenic 72
cytotoxic 77
hepatoprotective 84
immune-modulatory 148
synergistic 25, 73, 85
Encephalo myocarditis 69
Endocytosis 106
Endoribonuclease 49
Enterococcus faecalis 83
Enzyme hydrolysates 69, 79
Epidemic diarrhea virus 63
Equine 70, 80, 81, 97
arteritis virus (EAV) 70, 80, 81
coronavirus (ECoV) 97
influenza virus (EIV) 80
Escherichia coli 72, 83, 117
Essential oils 25, 70, 71, 73, 75, 77, 78, 79,
80, 81, 85
Exoribonuclease 49

F

Factors 84, 100, 101, 144
transcription 84

Pharmaceuticals for Targeting Coronaviruses 191

transforming growth 100
tumor necrosis 100, 101, 144
Feline 63, 67, 97
coronavirus (FCoV) 97
infectious peritonitis virus 63
Fibrosis 101
Fluorescence resonance energy transfer
(FRET) 121
Food and drug administration (FDA) 66, 112,
118
Free energy perturbation (FEP) 45, 118
FRET-based assay 178
Fusion 24, 33, 103, 104, 105, 110, 122, 123
machinery 104
peptide 123
process 123
virus-cell 105

G

Glycocoumarin 68, 84
Glycoprotein 3, 104, 105, 107, 113, 122, 123
transmembrane 113
spike 104
Glycosides 73, 75, 84
monoterpene 73
triterpene 84
Granulocyte colony-stimulating factor
(GCSF) 66

H

Hemagglutinating encephalomyelitis virus
(HEV) 97
Heparin 122
Hepatitis 68, 69, 70, 75, 79, 82, 83, 84, 85, 86,
160, 174, 181
A virus (HAV) 68, 75, 174
B virus (HBV) 68, 69, 70, 75, 83, 84, 85,
86
C virus (HCV) 69, 83, 85, 160, 181
Herpes simplex 67, 68, 69, 70, 73, 74, 76, 78,
80, 81, 83, 84, 85
infections 73, 74

virus (HSV) 67, 68, 69, 70, 74, 76, 78, 80, 81, 83, 84, 85
virus infections 84
HIV 18, 66
 protease inhibitors 18
 therapy 66
Homology modeling techniques 75
Human 63, 64, 65, 68, 69, 82, 83, 84, 102, 162, 181
 coronaviruses 63, 64, 65, 102, 162
 immunodeficiency virus (HIV) 68, 69, 82, 83, 84, 181
 induced immunodeficiency syndrome 82
Hydrogen-bonding interactions 44, 166, 175, 177, 178
Hypercytokinemia 142
Hyperlipidemia 146
Hyperthyroidism 73

I

Immune 99, 142, 144, 152
 booster 144
 homeostasis 142
 hyperactivity 99
 system response 152
Immunity 143, 145, 146
 antiviral 143
 booster 146
Immunodeficiency virus 82
Infectious 63, 67, 68, 69, 70, 77, 85, 97, 101
 bronchitis virus (IBV) 67, 68, 69, 70, 77, 85, 97
 diseases 63, 101
 laryngotracheitis viruses 69
Inflammation 149, 150, 151
 allergic 149
 respiratory 149
Influenza virus 69, 72, 75, 83
 pathogenic avian 72
Interactions, protein-protein 23
International committee on taxonomy of viruses (ICTV) 63, 98, 102

Intramolecular hydrogen-bonding interaction 173

J

Japanese traditional Kampo medicine system 82

K

Kalonji seed powder 146
Kaposi's sarcoma herpes virus (KSHV) 68, 85
Kidney diseases 82

L

Ligand-based drug design (LBDD) 1, 5
Lung 99, 150
 damage 99
 disorders 150
Lymphadenopathy 99
Lymphocytes 85, 101

M

Madin-Darby Canine kidney 73
Marine natural products (MNP) 19, 125
Medicinal plant-based antiviral therapeutics 65
Medicine, prophylactic 143
Mediterranean climate 71, 74
Membrane fusion 4, 105, 107, 123
 protein-mediated 123
MERSCoV viruses 158
Middle East respiratory syndrome (MERS) 3, 42, 44, 63, 64, 86, 102, 140, 159
Molecular 10
 docking technique 10
Molecular dynamics 17, 23, 24, 28, 29, 30, 44, 47, 49, 51, 124, 126
 techniques 51
Monspeliensis 71, 72
Murine hepatitis Virus (MHV) 63, 97

Subject Index

N

Nasal decongestion 149
Nasya Therapy 147, 149
Natural 27, 74, 125, 139
 herbal medicines 139
 marine inhibitors 125
 Marine Product 125
 Medicine Research 74
 sources 27
Nervous tension 73, 75
Newcastle disease 68, 69, 76, 78
 virus (NDV) 68, 69, 76, 78
Nonenveloped murine norovirus (NMN) 70
Non-structural proteins (NSPs) 3, 4, 7, 104
Nosocomial transmission 100
Novel 62, 149
 corona virus disease 62
 coronavirus infection progression 149
Nyctereutes procyonoides 97

O

Oil(s) 25, 77, 81, 85
 essential garlic 25
 officinalis 77
 oregano 81
 peppermint 85
Oleoresin, flammable 71
Oleuropein glycosides 69, 79
Origanum 76, 79
 majorana 76, 79
 minutiflorum 79
Outbreak 1, 2, 96
 of pneumonia 2, 96
 viral 1
Oxytetracycline 8

P

Pain, menstrual 147
Pancoronavirus fusion inhibitor 123
Pandemic 2, 52, 63, 64, 96, 138, 139, 142,
 158, 159, 180

Pharmaceuticals for Targeting Coronaviruses 193

COVID-19 158
 virus 2
Parasitic infections 118
Peptides 24, 107, 123, 160, 161, 166
Peptidomimetic 166, 168, 170, 176, 180
 drugs 180
 inhibitor 166, 168, 170, 176
Phagocytosis 79
Plant-based 62, 66
 anti-coronavirus agents 62
 antiviral therapeutics 66
Plants 73, 82
 honey 73
 liquorice 82
Pneumonia 2, 63, 96
 life-threatening 63
Pogostemonis herba 151
Polio viruses 69, 78
Porcine epidemic diarrhea virus (PEDV) 97
Pro-inflammatory cytokines (PIC) 83, 99, 100,
 142
Properties 67, 72, 73, 75, 78, 81, 119, 138,
 143, 144
 anti-inflammatory 72
 antiviral 75, 78, 81
 immune enhancer 67
 immune-modulator 138
 immune-modulatory 143, 144
 therapeutic 73, 119
Protease 79, 114, 120, 121, 181
 cathepsins chymase-type 114
 enzymes 79
 inhibitors 181
 viral 120, 121
Proteasome 121
Protein(s) 3, 6, 8, 9, 10, 13, 23, 24, 25, 30, 31,
 44, 48, 49, 51, 78, 84, 99, 101, 103, 104,
 105, 107, 108, 109, 110, 111, 112, 119,
 120, 142
 amino acid 108
 apoptosis inhibitor 78
 chemoattractive 101
 data bank (PDB) 13, 25, 44, 49, 51
 genes encoding structural/accessory 112
 human cell surface spike 142

human spike SARS-CoV2 99
inflammatory macrophage 101
integrase 120
kinase 78, 84
multivalent RNA binding 110
nucleocapsid 103, 109
viral replicase 104
Proteolysis 25, 160
Proteolytic processing 105, 162
Pseudomonas 72, 83
 aeruginosa 72
 fluorescens 83

Q

Qingfei paidu decoction (QPD) 151
Quantitative structure-activity relationship (QSAR) 5

R

Receptor-binding domain (RBD) 23, 24, 99, 104, 105, 106, 110, 123
Resistance 51, 86, 112
 HSV-1 infectivity 86
 mutation-mediated drug 112
Respiratory 2, 67, 70, 77, 80, 83, 102, 142, 145, 147, 148, 150, 151
 airways inflammation 148
 disorders 150, 151
 droplets 2, 142
 illness 145
 infection 147
 syncytial virus (RSV) 70, 77, 80, 83, 148
 syndrome 102
 tract infections 67, 83
Rhus coriaria 62, 67, 70, 86
Rift Valley fever virus (RVFV) 69, 83
RNA 4, 75, 76, 103, 104, 110, 120
 and DNA viruses 76
 dependent RNA polymerase 4, 75, 104, 110
 genome 103
 viral 110, 120
Rosemary 62, 67, 68, 74, 75, 76

dried 75
oil 75
plants 74
Rosmarinus officinalis 62, 67, 68, 74, 75, 76, 77
Ross River virus (RRV) 69, 83
Rotavirus 69, 79
 infections 79

S

Salvia officinalis 69, 73, 76, 85
SAR analysis 158, 159
SARS 68, 69, 96, 98, 148, 150
 associated virus 148
 coronavirus 68, 69, 150
 outbreaks 96, 98
SARS-CoV-2 1, 62, 66, 98, 101, 118, 119, 123, 124, 180
 combat 1, 62
 inhibitors of 124, 180
 infection 66, 101, 123
 protease 118, 119
 RNA polymerase 119
 virus 98
SARS-CoV 96, 100, 108, 110, 144
 helicase enzyme 144
 infections 96, 100
 protein 108, 110
Satureja 79, 85
 hortensis 79
 montana 85
 thymbra 85
SBDD techniques 1, 2, 47, 52
Screening techniques 38
Seroiridoids 78
Severe acute respiratory syndrome-coronavirus 159
Sindbis virus 83
Socioeconomic movement 140
Solanum 150
 indicum 150
 surattense 150
Sore throat 63, 67, 100, 146

Subject Index

SPROUT software 38
Structure-activity relationship (SAR) 161, 169
Swine hemagglutinating encephalomyelitis
 Virus 97
Synthesis 9, 38, 51, 75, 109, 162, 172, 175,
 177
 inhibiting RNA 9
 regulating viral RNA 109
 solid-phase 162
 virus compounds 75
System 24, 65, 113, 142, 143, 160
 autoimmune 65
 cardiovascular 113
 catalytic 24
 gastrointestinal 160
 respiratory 143
 transport 160
 world's healthcare 142

T

TCM theory 151
Techniques 5, 6, 7, 22, 23, 37, 38, 39, 52, 125,
 179
 bioinformatic 7
 computational 6, 23, 125
Therapies 64, 143
 immune-modulators 143
 nucleic acid-based 64
Toll-like receptor (TLR) 101
Traditional 8, 82, 138, 139, 143, 150, 151, 152
 Chinese medicine (TCM) 8, 82, 138, 139,
 143, 150, 151
 Indian medicines (TIM) 138, 143
 medicine systems 138, 139, 152
Transmissible gastroenteritis virus (TGEV)
 97, 166
Treatment of upper respiratory tract infection
 151
Turkey coronavirus (TCoV) 97

U

Upper respiratory tract infections 72, 151

Pharmaceuticals for Targeting Coronaviruses 195

V

Vaccines 1, 52, 64, 65, 66, 86, 114, 139
Vero cells, infected 121
Vesicular stomatitis virus (VSV) 68, 69, 70,
 76, 83
Viral 1, 51, 63, 65, 69, 74, 78, 79, 83, 85, 86,
 99, 110, 112, 116, 118, 119, 121, 122,
 124, 139, 148, 149, 158, 159, 162
 diseases 1, 63, 65, 79, 83
 hemorrhagic septicemia virus (VHSV) 69,
 78
 infections 74, 79, 83, 85, 86, 122, 149
 pneumonia 99
 polymerase 124
 replication 51, 65, 110, 112, 116, 118, 119,
 121, 148, 158, 162
 transmissions 139, 159
Virtual screening methods 9
Virus 62, 65, 78, 84, 86, 107, 108, 112
 infection 65, 78, 84, 86
 like particles (VLPs) 107, 108
 related diseases 62
 replication 112

W

Waals interactions 18

X

X-ray crystallography 177, 179

Z

Zika virus 67, 68, 69, 83
Zingiber officinale 146



Luciana Scotti

She holds a degree in Pharmaceuticals-Biochemistry obtained at the Faculty of Pharmaceutical Sciences of the University of São Paulo (USP) (1994). Subsequently, he completed a Master's, Doctorate and Post-Doctorate in Molecular Modeling at USP. She holds the Commendation of Pharmaceutical Merit. She is a voluntary permanent accredited professor at the Postgraduate Program of Bioactive Natural and Synthetic Products at the Federal University of Paraíba (UFPB), studying a postgraduate course in Food Science and is a pharmacist at the University Hospital.



Marcus T. Scotti

Prof. Marcus Tullius Scotti studied chemical engineering at Universidade de São Paulo (USP - São Paulo University) and finished his degree in 1999. Later, he worked for four years in a Brazilian electronics and telecommunications services company called Gradiente. At the same time, he started to specialize in the field of Industrial Administration at the University of São Paulo. After that, he started post-graduation in organic chemistry at the University of São Paulo in 2003, and finished his Master's in 2005 and Ph.D. in 2008. In January 2009, he moved to João Pessoa and started to work as a Professor of Organic Chemistry at the Universidade Federal da Paraíba (Federal University of Paraíba), Brazil. At the beginning of 2014, he completed his Post-doc in cheminformatics at the Universidade Nova de Lisboa, Portugal. Prof. Marcus' research interests lie in the area of chemistry of the natural products, acting on the following subjects: QSAR, Virtual Screening, molecular descriptors and chemotaxonomy using cheminformatics methods using several statistical tools and machine learning algorithms.